ArticleFrontiers in neuroscience2021
Attenuated Postprandial GLP-1 Response in Parkinson's Disease.
Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06460038 (Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Parkinson Disease and the Gut: A Primer for Gastroenterologists.The American journal of gastroenterology · 2025Review
- Gut: The gate and key to brain.Chinese medical journal · 2025Review
- Enteroendocrine cells: the gatekeepers of microbiome-gut-brain communication.NPJ biofilms and microbiomes · 2025Review
- The Gut-Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications.Movement disorders clinical practice · 2025Review
- Gut neuropeptide involvement in Parkinson's disease.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- The gut-brain axis in early Parkinson's disease: from prodrome to prevention.Journal of neurology · 2025Review
- GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults.NPJ Parkinson's disease · 2024Article
- Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.Frontiers in immunology · 2023Review
- Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1.Current neurology and neuroscience reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The incretin hormone glucagon-like peptide 1 (GLP-1) has neuroprotective effects in animal models of Parkinson's disease (PD), and GLP-1 receptor agonists are associated with clinical improvements in human PD patients. GLP-1 is produced and secreted by intestinal L-cells in response to consumption of a meal. Specifically, intestinal microbiota produce short chain fatty acids (SCFA) which, in turn, promote secretion of GLP-1 into the systemic circulation, from which it can enter the brain. Our group and others have reported that PD patients have an altered intestinal microbial community that produces less SCFA compared to age-matched controls. In this report, we demonstrate that PD patients have diminished GLP-1 secretion in response to a meal compared to their household controls. Peak postprandial GLP-1 levels did not correlate with PD disease severity, motor function, or disease duration. These data provide the scientific rationale for future studies designed to elucidate the role of GLP-1 in the pathogenesis of PD and test the potential utility of GLP-1-directed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.